China Clears 11 Innovative Medical Devices for Special Review Track

Leave a reply

Beijing, Aug 25, 2026 — China’s Center for Medical Device Evaluation (CMDE) unveiled the 14th batch of innovative medical device special review applications for 2026, clearing 11 products for an expedited regulatory pathway spanning advanced oncology therapy, cardiovascular implants, and brain-computer interfaces.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	Announcement of Review Results for Special Review Applications of Innovative Medical Devices (No. 14, 2026)
Legal basis	NMPA Announcement [2018] No. 83 (Special Review Procedure for Innovative Medical Devices)
Products cleared	11
Public comment period	Aug 25, 2026 – Sept 8, 2026
Contact	gcdivision@cmde.org.cn

Products Entering Special Review

The 11 devices span therapeutic areas from oncology to neurology:

No.	Product	Applicant	Category
1	Disposable Steep-Pulse Ablation Electrode Needle	Hunan Eweid Medical Device Co., Ltd.	Tumor ablation
2	Aortic Root Patch	Beijing Balance Medical Technology Co., Ltd.	Cardiovascular surgery
3	Aortic Valve Replacement System	Shenzhen Jianxin Medical Technology Co., Ltd.	Structural heart
4	Boron Neutron Capture Therapy System	Huapeng Boron Neutron Technology (Hangzhou) Co., Ltd.	Radiation oncology
5	Bioresorbable Left Atrial Appendage Occluder	Shanghai Shape Memory Alloy Material Co., Ltd.	Interventional cardiology
6	Artificial Corneal Endothelial Membrane Patch	Aiyan Medical Co., Ltd.	Ophthalmology
7	Implantable Brain-Computer Interface Neurostimulator	Beijing PINS Medical Equipment Co., Ltd.	Neurology / neurotechnology
8	Implantable Tibial Nerve Stimulation System	Hangzhou Shenluo Medical Technology Co., Ltd.	Neuromodulation
9	Human Circulating Tumor Molecular Residual Disease Detection Kit (CPA Sequencing)	Guangzhou Burning Rock Medical Laboratory Co., Ltd.	Oncology diagnostics
10	Focused Ultrasound Neuromodulation Device	Chongqing Haifu Medical Technology Co., Ltd.	Therapeutic ultrasound
11	Absorbable Dural Sealant Glue	Shandong Junxiu Biotechnology Co., Ltd.	Neurosurgery

Market Impact Analysis

The 14th batch highlights Beijing’s continued prioritization of high-risk, high-innovation devices that address unmet clinical needs. Notable entries include Huapeng Boron Neutron Technology’s boron neutron capture therapy (BNCT) system—a cutting-edge radiation modality for refractory cancers—and Beijing PINS Medical’s implantable brain-computer interface neurostimulator, reflecting China’s strategic push into neurotechnology and advanced neuromodulation.

Cardiovascular devices dominate the roster with three entries, including an aortic valve replacement system and a bioresorbable left atrial appendage occluder, signaling sustained investor and regulatory interest in structural heart interventions. The inclusion of an artificial corneal endothelial membrane patch and an absorbable dural sealant glue underscores expansion into specialized surgical niches with limited existing treatment options.

Burning Rock’s circulating tumor molecular residual disease (MRD) detection kit, using combined probe anchor polymerization sequencing, positions the company to compete in the rapidly growing minimal residual disease monitoring market, a segment increasingly valued for post-surgical cancer recurrence surveillance.

Regulatory Caveats

CMDE emphasized that the public announcement does not constitute formal admission into the special review procedure; final eligibility depends on conclusive review outcomes. Entry into the special review track does not equate to regulatory confirmation of safety or efficacy. Applicants must continue development and submit formal registration applications, which will be evaluated under early engagement, dedicated reviewer, and scientific review principles—without reduced standards or abbreviated procedures.

Forward-Looking Statement

Industry analysts expect the 11 devices to benefit from expedited CMDE review timelines, typically compressing standard approval cycles by 30% to 50% for innovative products. The batch’s diversity—from BNCT systems to brain-computer interfaces—suggests regulators are casting a wide net for breakthrough technologies rather than concentrating on a single therapeutic area. Companies with pipeline candidates in neuromodulation, advanced radiation therapy, and molecular diagnostics should view the special review pathway as increasingly accessible, though the caveat on unchanged evidentiary standards means clinical trial requirements remain rigorous. Final special review determinations are expected by late September 2026, barring substantive objections during the two-week comment window.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260825110558111.html

China Backs Centralized Production of Hospital Preparations in TCM

Leave a reply

Beijing, Aug 14, 2026 — China’s National Medical Products Administration (NMPA) endorsed centralized manufacturing models for hospital traditional Chinese medicine (TCM) preparations in an official reply to a National People’s Congress proposal, outlining a regulatory framework that shifts traditional formulas toward regional production hubs while tightening quality controls and streamlining filing requirements.

Policy Snapshot

Attribute	Detail
Document	Reply to Proposal No. 3936, 14th NPC 4th Session
Proposer	Deputy Fan Zhen
Issuers	NMPA; National Administration of Traditional Chinese Medicine
Key regulation	Revised Drug Administration Law Implementing Regulations (effective May 15, 2026)
Core focus	Hospital preparations; centralized production; regional formulation centers

Regulatory Streamlining

The NMPA highlighted that the revised Drug Administration Law Implementing Regulations, effective May 15, 2026, codify simplified pathways for hospital TCM preparations. Institutions using traditional preparation methods need only file with provincial regulators rather than seek full approval. Formulations with a five-year or longer clinical use history within the same hospital are exempt from pharmacodynamics and single- and repeat-dose toxicity studies.

The agency also clarified that outsourcing preparation no longer requires a separate regulatory license; hospitals need only file with provincial authorities as the delegating party. The rules mandate that hospital legal representatives and primary executives bear full responsibility for formulation quality, and require provincial regulators to decide on inter-hospital transfer applications within five working days.

The NMPA pointed to its 2023 measures on TCM scientific supervision, which encourage hospitals to use big data, artificial intelligence, and real-world evidence to study clinical positioning, target populations, and dosage regimens for institutional preparations. The framework explicitly supports converting proven hospital formulations with distinct advantages and low adverse-event profiles into new drug candidates.

Quality Safeguards

Regulators pledged intensified inspections of preparation and use processes, with particular scrutiny on outsourced manufacturing by small TCM clinics. The NMPA urged hospitals to establish pharmacovigilance systems for adverse reaction monitoring and endorsed multi-center clinical studies through inter-hospital transfers. The framework requires full traceability of raw materials, production controls, and quality testing.

Centralized Production Push

In the most significant policy signal, the NMPA and NATCM endorsed piloting regional formulation centers to enable shared production, unified quality control, and consolidated distribution of hospital TCM preparations. The agencies said they would draw on national drug traceability system experience to explore full-process digital tracking for institutional formulations, and will summarize local pilot experiences to refine centralized manufacturing and transfer policies.

Market Impact Analysis

The endorsement of regional formulation centers marks a structural shift for China’s hospital TCM sector, which has historically relied on fragmented in-house preparation labs. Centralized production could reduce per-unit manufacturing costs and standardize quality across institutions, but may force smaller hospitals to abandon independent formulation capabilities and rely on regional hubs.

The exemption of five-year traditional formulas from toxicity studies lowers the barrier for heritage formulations to achieve regulatory status, potentially accelerating the pipeline of hospital-developed drugs toward new drug conversion—a pathway the NMPA explicitly supports. For pharmaceutical contract manufacturers, the regional hub model creates new partnership opportunities with hospital networks, particularly in provinces with dense TCM institution clusters.

Forward-Looking Statement

Industry analysts expect the NMPA to release detailed regional formulation center guidelines within 12 to 18 months, following pilot program evaluations. The convergence of simplified filing rules, digital traceability mandates, and centralized production incentives suggests Beijing is positioning hospital TCM preparations as a controlled but strategically important bridge between traditional practice and modern pharmaceutical manufacturing. Companies with expertise in TCM formulation technology and pharmaceutical logistics are likely to benefit as provincial governments begin tendering regional hub contracts in late 2026 and 2027.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/zwgk/jyta/rdjy/20260825155646136.html

China Suspends Avinger Medical Devices Over Failed Inspection

Leave a reply

Beijing, Aug 25, 2026 — China’s National Medical Products Administration (NMPA) suspended the import, sale, and use of three medical devices from U.S.-based Avinger, Inc. after the company failed to submit required documentation for an overseas inspection, marking a rare enforcement action against a foreign manufacturer for procedural non-compliance.

Regulatory Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 80
Target company	Avinger, Inc. (United States)
Effective date	Aug 25, 2026
Legal basis	Provisions for Overseas Inspections of Drugs and Medical Devices, Article 28; Medical Device Supervision and Administration Regulations
Violation	Failure to submit power of attorney, product information forms, and site master files within required timeframe
Finding	Non-compliance with China’s Medical Device Production Quality Management Specification (GMP)

Affected Products

Product	Registration No.	Description
Pantheris Catheter	国械注进20263010082	Single-use peripheral vascular plaque resection catheter
Pantheris SV Catheter	国械注进20253010610	Single-use peripheral vascular plaque resection catheter
Lightbox 3 OCT Imaging Console	国械注进20263010131	Intravascular optical coherence tomography and power control device

Enforcement Rationale

Under the NMPA’s 2026 overseas inspection plan, regulators scheduled an on-site review of Avinger’s manufacturing and quality systems. Avinger did not provide the mandated authorization letter, product status documentation, or site master file within the stipulated deadline. Pursuant to Article 28 of the overseas inspection regulations, the NMPA classified the deficiency as a failure to meet China’s medical device GMP standards, triggering an immediate suspension of all commercial activities for the three registered products.

Market Impact Analysis

The suspension halts Avinger’s commercial access to China’s market for its peripheral vascular and intravascular imaging portfolio. The Pantheris catheter line, used in peripheral artery disease interventions, and the Lightbox 3 OCT console, used for real-time intravascular imaging, are now barred from importation, distribution, and clinical use nationwide. For Chinese hospitals and distributors, the ban creates an immediate supply gap in peripheral atherectomy and OCT-guided vascular procedures, potentially shifting demand to competing devices from domestic or other international manufacturers.

The enforcement signals heightened NMPA willingness to invoke suspension powers for procedural lapses, not just product quality failures. By acting on documentation deficiencies rather than clinical adverse events, regulators are raising the compliance bar for foreign manufacturers navigating China’s overseas inspection regime.

Forward-Looking Statement

Industry analysts expect Avinger to face a lengthy reinstatement process requiring full documentation submission, followed by a rescheduled inspection and potential corrective action verification. The case is likely to prompt other U.S. and European device makers to audit their China regulatory file readiness, particularly authorization letters and site master files, ahead of scheduled 2026 overseas inspections. With Beijing intensifying scrutiny of imported medical devices, manufacturers with pending NMPA registrations should treat documentation compliance as a critical path item to avoid similar market access disruptions.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20260825165610199.html